A quiet revolution is underway in modern medicine: Drug development is aiming to move from managing disease to correcting it through RNA and gene-editing therapies. But delivering these treatments safely and precisely to the right cells remains a major hurdle—especially in hard-to-target organs like the brain and kidneys.

Now, researchers led by a University of Ottawa Faculty of Medicine team offer highly compelling evidence that an elegant, nature-inspired solution lies in ultra-tiny, bubble-like structures called small extracellular vesicles (sEVs). These metabolic messengers, refined over millions of years of evolution, carry RNA—a nucleic acid that is a chemical cousin of DNA—and other molecules between cells.

In a nutshell, the research team’s new findings show that not all sEVs are alike: their cell of origin determines where they travel, with certain vesicles naturally targeting specific tissues in the body.